Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 178

Precision Therapy to Overcome Chemoresistance in Pediatric Glioblastoma

Glioblastoma (GBM) remains one of the most aggressive and lethal forms of cancer. Despite the best available treatment options including surgical resection, radiotherapy, and chemotherapy, prognosis is poor in glioblastoma, with a median overall survival of 14 months.1Currently, temozolomide (TMZ) is the preferred chemotherapeutic drug in the treatment of GBM ...

Targeting hypoxia and mitochondrial metabolism with repurposing drugs as an ...

Abstract Diffuse intrinsic pontine glioma (DIPG) is a rare and incurable brain tumor that arises in the brainstem of children predominantly between the ages of 6 and 9.  Unlike many brain tumors, DIPGs cannot be removed through surgery due to its sensitive location. The standard of care today remains radiation therapy (...

Exploiting the use of exosomal miRNAs from DIPG/DMG liquid ...

An unmet need in DIPG/DMG, is  the lack of reliable biomarkers. Those are urgently needed as alternative/complementary approach to neuroradiological imaging, not only for diagnosis but for disease monitoring. In this context, liquid biopsy could represent a valuable, non-invasive source for biomarkers in DIPG/DMG. From previous ...

Epigenetic Targeted Therapy and Resistance in AT/RT

Pediatric rhabdoid tumor in the brain, atypical teratoid/rhabdoid tumor (AT/RT), is a highly malignant brain tumor that has a very poor prognosis despite aggressive treatment. The development of new, effective therapeutic approaches for AT/RT has been hindered by a lack of specific therapeutic targets. It is necessary ...

Glycomic Tumor Neoantigen Discovery in Diffuse Intrinsic Pontine Glioma (DIPG)

Diffuse intrinsic pontine glioma (DIPG) is a horrific childhood brain cancer. Patients die within 2 years of diagnosis. Treatments include radio- and chemotherapy, however the tumor always regrows due to resistance of the tumor cells to therapy. Understanding and tackling resistance is key to improve survival of patients with DIPG. We ...